"Another important caveat to our findings is that the threshold for defining cardiotoxicity was set at >30% demonstrating loss of myocardial viability, which limits the definitive interpretation of the results for those drugs with detected viability close to that threshold."
Taxane - Docetaxel - 71.3 ± 6.8%
Topoisomerase inhibitor - Topotecan - 72.2 ± 6.4%
Where does the statistical significance threshold come from? And given these two drugs are close to the threshold, can they also be considered additional potential CPACS opportunities even though HCM viability remained slightly higher than the threshold?
- Forums
- ASX - By Stock
- RAC
- Cardioprotection thread
Cardioprotection thread, page-222
-
-
- There are more pages in this discussion • 684 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
-0.020(1.18%) |
Mkt cap ! $282.9M |
Open | High | Low | Value | Volume |
$1.69 | $1.69 | $1.66 | $65.89K | 39.52K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 397 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 4523 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 397 | 1.670 |
3 | 9681 | 1.655 |
5 | 49001 | 1.650 |
3 | 9200 | 1.640 |
2 | 6532 | 1.630 |
Price($) | Vol. | No. |
---|---|---|
1.680 | 4523 | 1 |
1.685 | 5085 | 1 |
1.690 | 3000 | 1 |
1.700 | 4967 | 4 |
1.715 | 532 | 1 |
Last trade - 12.52pm 18/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |